Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechs
Thursday, September 10, 2026 · first reported by Fierce Biotech and 1 other
Frazier Life Sciences closed a $1.1B venture fund focused on early and growth-stage investments in small and midsize biotechnology companies.
- Size
- $1.1B
- Stage
- Final close
- Asset class
- Venture
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
2 sourcesMore in Venture capital
From the same day- Luma closes $410m debut life-sciences fund after scoring $1.55bn first exitAltAssets
- Pinegrove Closes First Venture Fund-of-Funds Since Absorbing SVB CapitalWSJ
- Warburg Pincus on the cusp of wrapping up its 15th flagship growth fundBuyouts Insider
- SEC Charges Adit Ventures Management, its CEO and Affiliated General Partners for Alleged FraudJD Supra
- Galen Weston Jr. commits $180-million more to venture capital through privately held Wittington VenturesThe Globe and Mail
- NKU launches venture capital fund, makes first investment in local startupThe Business Journals